Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of RGT-264 Phosphate Tablets in Subjects With Advanced Solid Tumors

NCT05764915 is registered in ClinicalTrials.gov with Regor Pharmaceuticals Inc. as lead sponsor.

NCT NCT05764915
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05764915 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of RGT-264 Phosphate Tablets in Subjects With Advanced Solid Tumors
Lead sponsor
Regor Pharmaceuticals Inc.
Phase
Phase 1
Overall status
Terminated
Start date
February 15, 2023
Completion date
February 20, 2024
Enrollment
11 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor